EGFR and non-small cell lung carcinoma: Additionally, patients with EGFR-mutated NSCLC harboring TP53 mutations are often unlikely to derive clinical benefit (Molina-Vila et al., 2014; Canale et al., 2017; Zhang et al., 2019).